Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UMPS | P11172 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.41 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31685623 | 0.89 | CYP2C19 (0.47) | UMPSCYP2C19HIF1ANT5ESLC28A1 | |
| SCHEMBL15810704 | 0.83 | SLC28A1 (0.59) | UMPSSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL17211017 | 0.83 | SLC28A1 (0.59) | UMPSSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL40872 | 0.83 | SLC28A1 (0.59) | UMPSSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18852581 | 0.83 | SLC28A1 (0.59) | UMPSSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18512949 | 0.83 | SLC28A1 (0.59) | UMPSSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL31685495 | 0.83 | UMPS (0.77) | UMPSNT5EP2RY2P2RY6P2RY14 | |
| SCHEMBL31685475 | 0.80 | SLC28A1 (0.44) | UMPSCYP2C19HIF1ASLC28A1SLC28A2 | |
| SCHEMBL31685524 | 0.80 | P2RY2 (0.42) | CYP2C19HIF1AADORA1P2RY2 | |
| SCHEMBL4319312 | 0.79 | SLC28A1 (0.68) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | UMPS 770/4885CYP2C19 4442/4885HIF1A 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.